Close Menu

Closing the Gap between Preclinical Biologic Development and Clinical Application in Rheumatoid Arthritis

Journal Authors: 
Issue: 
DOI: 
10.7727/wimj.2014.100
Pages: 
312–3
 
The Editor,
Sir,

Rheumatoid arthritis (RA) is a chronic autoimmune disease; deferment and relapse of aggressive synovitis finally leads to destruction of joint cartilage and bone, and that is the main hazard of the disease. In recent years, biologic reagents have become a hot spot of RA treatment research, owing to their higher specificity and fewer side effects than existing non-biologic disease-modifying and anti-inflammatory drugs. 

Accepted: 
23 Apr, 2014
PDF Attachment: 
e-Published: 15 May, 2015
Top of Page